Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Pas-004 in Ongoing Phase 1 Clinical Trial
Pasithea Therapeutics宣佈完成第2組招募和初次給藥，並在持續的1期臨床試驗中獲得正面的安全審查委員會（SRC）建議，針對Pas-004。